JP2006511604A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006511604A5 JP2006511604A5 JP2005502468A JP2005502468A JP2006511604A5 JP 2006511604 A5 JP2006511604 A5 JP 2006511604A5 JP 2005502468 A JP2005502468 A JP 2005502468A JP 2005502468 A JP2005502468 A JP 2005502468A JP 2006511604 A5 JP2006511604 A5 JP 2006511604A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- sleep
- methyl
- hydrogen
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 208000001640 Fibromyalgia Diseases 0.000 claims description 6
- 230000000392 somatic effect Effects 0.000 claims description 5
- 208000027520 Somatoform disease Diseases 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 208000012839 conversion disease Diseases 0.000 claims description 2
- 208000027753 pain disease Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 12
- 230000037322 slow-wave sleep Effects 0.000 claims 10
- 206010022437 insomnia Diseases 0.000 claims 8
- 208000019906 panic disease Diseases 0.000 claims 7
- 208000019116 sleep disease Diseases 0.000 claims 7
- 208000008811 Agoraphobia Diseases 0.000 claims 6
- 206010041250 Social phobia Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 208000020685 sleep-wake disease Diseases 0.000 claims 5
- 102000002265 Human Growth Hormone Human genes 0.000 claims 4
- 108010000521 Human Growth Hormone Proteins 0.000 claims 4
- 239000000854 Human Growth Hormone Substances 0.000 claims 4
- 208000013200 Stress disease Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 208000017667 Chronic Disease Diseases 0.000 claims 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 2
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 2
- 101000997570 Homo sapiens Appetite-regulating hormone Proteins 0.000 claims 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000010340 Sleep Deprivation Diseases 0.000 claims 2
- 206010041347 Somnambulism Diseases 0.000 claims 2
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 2
- 206010020765 hypersomnia Diseases 0.000 claims 2
- 230000001788 irregular Effects 0.000 claims 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 2
- 201000003631 narcolepsy Diseases 0.000 claims 2
- 230000001537 neural effect Effects 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 230000007958 sleep Effects 0.000 claims 2
- 201000002859 sleep apnea Diseases 0.000 claims 2
- 230000003860 sleep quality Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006199 Parasomnias Diseases 0.000 claims 1
- 206010062519 Poor quality sleep Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010041247 Social fear Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 claims 1
- 208000022266 body dysmorphic disease Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 1
- 229960001233 pregabalin Drugs 0.000 claims 1
- 208000033914 shift work type circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 208000033039 Somatisation disease Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 208000016994 somatization disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43349102P | 2002-12-13 | 2002-12-13 | |
| US48348203P | 2003-06-27 | 2003-06-27 | |
| PCT/IB2003/005684 WO2004054565A1 (en) | 2002-12-13 | 2003-12-03 | Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006511604A JP2006511604A (ja) | 2006-04-06 |
| JP2006511604A5 true JP2006511604A5 (https=) | 2007-10-25 |
Family
ID=32600152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005502468A Withdrawn JP2006511604A (ja) | 2002-12-13 | 2003-12-03 | 線維筋痛症及び関連する他の障害の治療のためのプレガバリン及びその誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20040138305A1 (https=) |
| EP (1) | EP1572187A1 (https=) |
| JP (1) | JP2006511604A (https=) |
| KR (1) | KR100845932B1 (https=) |
| AU (1) | AU2003286300A1 (https=) |
| BR (1) | BR0317263A (https=) |
| CA (1) | CA2508297A1 (https=) |
| MX (1) | MXPA05006209A (https=) |
| PL (1) | PL377662A1 (https=) |
| TW (1) | TW200412939A (https=) |
| WO (1) | WO2004054565A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL189872B1 (pl) | 1996-07-24 | 2005-10-31 | Warner Lambert Co | Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu |
| JP2007505095A (ja) * | 2003-09-12 | 2007-03-08 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | うつ病及び不安障害の治療のためのアルファ−２−デルタリガンド及びｓｓｒｉ及び／又はｓｎｒｉを含む組み合わせ |
| AU2007222112A1 (en) * | 2006-03-06 | 2007-09-13 | Pfizer Products Inc. | Alpha-2-delta ligands for non-restorative sleep |
| EP1857836B1 (en) * | 2006-05-15 | 2009-10-21 | Eldim Sa | Device and method for discriminating cerenkov and scintillation radiation |
| US20080161393A1 (en) * | 2006-12-08 | 2008-07-03 | Barrett Ronald W | Use of prodrugs of GABA analogs for treating disease |
| US7868043B2 (en) | 2008-01-25 | 2011-01-11 | Xenoport, Inc. | Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
| EP2250148B1 (en) | 2008-01-25 | 2016-08-17 | XenoPort, Inc. | Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use |
| ES2601852T3 (es) * | 2008-01-25 | 2017-02-16 | Xenoport, Inc. | Forma cristalina de sales de calcio de ácidos (3S)-aminometil-5-metil-hexanoicos y métodos de uso |
| ES2758554T3 (es) | 2009-12-08 | 2020-05-05 | Univ Case Western Reserve | Aminoácidos gama para tratamiento de trastornos oculares |
| US8580850B2 (en) | 2011-08-11 | 2013-11-12 | Xenoport, Inc. | Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use |
| ES2961655T3 (es) | 2013-01-18 | 2024-03-13 | Kemphys Ltd | Medicamento para tratamiento de enfermedad neuropática |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US4087544A (en) * | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
| US6197819B1 (en) * | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| US6372792B1 (en) * | 1996-04-26 | 2002-04-16 | Guy Chouinard | Method for treating anxiety, anxiety disorders and insomnia |
| PL189872B1 (pl) * | 1996-07-24 | 2005-10-31 | Warner Lambert Co | Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu |
| WO1998017627A1 (en) * | 1996-10-23 | 1998-04-30 | Warner-Lambert Company | Substituted gamma aminobutyric acids as pharmaceutical agents |
| WO1999008670A1 (en) * | 1997-08-20 | 1999-02-25 | Guglietta, Antonio | Gaba analogs to prevent and treat gastrointestinal damage |
| EP0974351A3 (en) * | 1998-04-24 | 2000-12-13 | Jouveinal | Medicament for preventing and treating gastrointestinal damage |
| EP1082306A1 (en) * | 1998-05-26 | 2001-03-14 | Warner-Lambert Company | Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel |
| JP2002520277A (ja) * | 1998-07-09 | 2002-07-09 | ワーナー−ランバート・カンパニー | 不眠症を治療する方法 |
| EP1121114B1 (en) * | 1998-10-16 | 2007-01-10 | Warner-Lambert Company Llc | Use of gaba analogs for the manufacture of a medicament for the treatment of mania and bipolar disorders |
| AU1602100A (en) * | 1998-11-25 | 2000-06-13 | Warner-Lambert Company | Improved gamma amino butyric acid analogs |
| AU3735000A (en) * | 1999-05-05 | 2000-11-21 | Warner-Lambert Company | Modulation of substance p by gaba analogs and methods relating thereto |
| RS50352B (sr) * | 1999-06-10 | 2009-11-10 | Warner-Lambert Company Llc., | Monosupstituisane 3-propil gama-aminobuterne kiseline |
| CA2449729C (en) * | 2001-06-11 | 2009-11-03 | Xenoport, Inc. | Prodrugs of gaba analogs, compositions and uses thereof |
| US6635675B2 (en) * | 2001-11-05 | 2003-10-21 | Cypress Bioscience, Inc. | Method of treating chronic fatigue syndrome |
| EP1471909A4 (en) * | 2002-01-16 | 2007-07-25 | Endo Pharmaceuticals Inc | PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |
-
2003
- 2003-12-03 EP EP03777043A patent/EP1572187A1/en not_active Withdrawn
- 2003-12-03 AU AU2003286300A patent/AU2003286300A1/en not_active Abandoned
- 2003-12-03 JP JP2005502468A patent/JP2006511604A/ja not_active Withdrawn
- 2003-12-03 MX MXPA05006209A patent/MXPA05006209A/es unknown
- 2003-12-03 BR BR0317263-5A patent/BR0317263A/pt not_active IP Right Cessation
- 2003-12-03 KR KR1020057010503A patent/KR100845932B1/ko not_active Expired - Fee Related
- 2003-12-03 PL PL377662A patent/PL377662A1/pl not_active Application Discontinuation
- 2003-12-03 WO PCT/IB2003/005684 patent/WO2004054565A1/en not_active Ceased
- 2003-12-03 CA CA002508297A patent/CA2508297A1/en not_active Abandoned
- 2003-12-09 US US10/731,225 patent/US20040138305A1/en not_active Abandoned
- 2003-12-12 TW TW092135200A patent/TW200412939A/zh unknown
-
2007
- 2007-05-18 US US11/804,789 patent/US20070238749A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008531714A (ja) | 不安障害の治療用及び／又は予防用の医薬組成物 | |
| JP2006511604A5 (https=) | ||
| BRPI0414347A (pt) | associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade | |
| JP2007506801A (ja) | モダフィニルおよび他の薬剤を含んでなる製薬学的組成物 | |
| RU2336077C2 (ru) | Альфа-аминоамидные производные, применимые в качестве антимигренозных средств | |
| EP1762237A1 (fr) | Utilisation de l'agomelatine pour l'obtention de médicaments destinés au traitement des troubles du sommeil chez le patient déprimé | |
| JP6960415B2 (ja) | 三叉神経痛を予防又は治療する目的のためのカルバメート化合物の使用 | |
| JP5341037B2 (ja) | 双極性障害を処置するための医薬を得るためのアゴメラチンの使用 | |
| JP7208139B2 (ja) | 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用 | |
| JP5017268B2 (ja) | 覚醒を改善する方法 | |
| JP2007503424A (ja) | 抗炎症剤として有用なα−アミノアミド誘導体 | |
| JP2011088919A (ja) | アゴメラチンとノルアドレナリン再取り込み阻害剤との新たな組み合わせ、及びそれを含有している医薬組成物 | |
| JP2006516576A5 (https=) | ||
| WO2008004067A2 (en) | Alpha-2-delta-1 selective compounds for disorders of the nervous system | |
| JP2024030188A (ja) | 女性のうつ症状を改善するための医薬組成物 | |
| AU2006209371B2 (en) | New association between agomelatine and a thymoregulatory agent, and pharmaceutical compositions containing it | |
| CN101242836A (zh) | 改善觉醒状态的方法 | |
| HK1152661A (en) | Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders |